Le Lézard
Classified in: Health
Subject: FDA

Abbott Announces FDA Clearance for its Alinitytm ci-series Next-generation Diagnostic Systems


ABBOTT PARK, Ill., Oct. 31, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) has secured U.S. Food and Drug Administration (FDA) 510(k) clearance for its Alinitytm ci-series instruments for clinical chemistry and immunoassay diagnostics. These innovative testing solutions were designed to help the lab more effectively address modern industry challenges, including aging populations, growing management of chronic diseases and increased access to care, which are driving increases in testing volume.

"Healthcare systems across the United States are under pressure to deliver better care for patients," said Brian Blaser, executive vice president, Diagnostics Products, Abbott. "Labs and healthcare systems are looking for complete solutions that help them operate more efficiently while contributing to better clinical decision making and helping improve patient outcomes. FDA clearance is a key first step in bringing this important innovation to our U.S. customers as we work to gain approval for the full Alinity portfolio of instruments and assays."

The Alinity ci-series is part of a unified family of personalized solutions that are engineered for flexibility and efficiency. The design is based on insights from thousands of customers, resulting in a number of benefits including:

The "Alinity c" clinical chemistry system, and the "Alinity i" immunoassay system, can operate individually or as an integrated Alinity ci-series unit, allowing for greater productivity in half the footprint of current diagnostics systems. In addition to the instrument clearance, several clinical chemistry and immunoassay tests are now cleared in the U.S. for the system, with a comprehensive menu of tests expected to be available within a year of launch. The Alinity ci-series obtained CE Mark earlier this year and is available in Europe, Middle East, Asia and Latin Americaii.

"Alinity ci was designed using a different approach. We went beyond traditional market research and spent countless hours with our customers, listening to their challenges and observing how they work," said John Frels, Vice President, Immunoassay and Clinical Chemistry Research and Development. "With customer insights as our roadmap, the Alinity ci is engineered to simplify diagnostic testing while ensuring speed, accuracy and performance."

About Alinity
The Alinity portfolio includes clinical chemistry, immunoassay, blood and plasma screening, point of care, hematology and molecular diagnostics, along with Abbott's AlinIQ?a first-of-its-kind, holistic suite of professional services that combines expertise with process analysis and informatics. Alinity is helping labs and hospital systems solve some of their most pressing challenges to deliver better patient care with fewer resources. More information is available at abbott.com/alinity.

About Abbott
At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world -- in nutrition, diagnostics, medical devices and branded generic pharmaceuticals -- that create more possibilities for more people at all stages of life. Today, 94,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal. 

i Dependent upon clinical chemistry and immunoassay test mix.
ii Instrument and test availability can vary by geography.

Abbott Logo (PRNewsFoto/Abbott)

 

SOURCE Abbott


These press releases may also interest you

at 00:31
ConnectedLife and Ocean Protocol announce their partnership to advance Parkinson's Disease diagnosis and treatment with safe sharing of patient-generated data. Photo - https://mma.prnewswire.com/media/838389/Trent_McConaghy_Founder.jpg By combining...

at 00:00
ICH GCP E6 R2 Meeting CRO-Vendor Oversight Requirements **An Interactive Workshop Presented by CenterWatch and Wool Consulting Group** March 27-28, 2019 Raleigh, NC...

at 00:00
Interstate Industries, Inc. d/b/a Hemi-Sync®, a leading conscious media company, has released a new title, Deep Connection: A Meditation for Two. Created and voiced by philosopher and best-selling author T!M FREKE, these meditations can transform...

at 00:00
The National Institute of Health estimated that Americans spend more than $36 billion on multivitamin supplements each year. But do the vitamins we take really contain the nutrients that are advertised? And how do we know for sure? That's why Jordi...

19 mar 2019
"We are thrilled with today's announcement by the federal government to support the creation of the Marathon of Hope Cancer Centres. Under this new Terry Fox Research Network, Canadian cancer centres, together with their research teams from coast to...

19 mar 2019
Physicians from several study sites involved in CalciMedica's initial acute pancreatitis clinical study of its CRAC channel inhibitor CM4620 (NCT03401109) and CalciMedica, Inc., presented a poster today at the 39th International Symposium on...



News published on 31 october 2017 at 09:00 and distributed by: